Member Info for Mars1

Gman ODXs tweet Friday night said the equipment was available

Most have seemed to have missed the whole point of the public statement made by ODX. Technically the contract has lapsed because DHSC has not notified an extension. If OdX had not stated they considered it had lapsed they would not have access to the equipment it would have to be kept available for DHSC production. Now if ODX can chase more deals and if they receive a commercial deal where they need the equipment they do not want to be sued by DHSC for being unable to fulfil the DHSC contract at some point in the future if and when DHSC put in an order. Without that clarification they could not pursue more orders.

However there is no reason why the recent results are from tests required by those interested parties

Sorry old news

https://www.proactiveinvestors.co.uk/companies/news/924797/nuformix-says-there-has-been-increased-interest-in-its-assets-and-their-potential-to-treat-covid-19-924797.html

Lansdown on the case, signed up DAM, largest in clinic next to Boots, but with a global twist (so better thanBoots?) and growing like crazy. So now has 100m tests for retail, go Lansdown. £29 per test boom

Sounds as though they have approval to use govt machines wow ser

100m tests into retail far better

There are those moments that exist when there are choices, we are at one of those moments. A blockbuster product that can help with lung fibrosis at the moment of an ageing population in the middle of a pandemic that increases lung scarring as an after affect. There is limited offering in the world with a significant market. Who will grasp the nettle? If the pharma want to be key players they will want this to be part of their portfolio

Far more beneficial selling to the market than DHSC what a tweet so oversold hope you didn’t
“ Omega Diagnostics
@OmegaDiagnostic
·
2h
"Omega continues to have access to the Government-funded equipment, and has brought Lansdown Strategic Capital on board to help secure contracts…
The first agreement – a deal with flight certification provider
@DAM_health”
"

Private market will be more lucrative, especially fit to fly through DAM will be a huge market, should think DAM are excited they have more capacity as the DHSC seem uninterested. Just need first approval. DAM may be the largest in clinic next to Boots but they also have fantastic growth in the global market. Omega have an exclusive contract for global growth. There is no way this should be priced as it is. DHSC should donate its equipment to ODX for leading them up the garden path as minimum in compensation.

One positive is the patents so far have been taken out in the US so some acceptability there, as far as IIs go they usually require a minimum liquidity level of £100m market cap before they can invest.

Deal now has to be with a global player, any U.S. pharma will have to be convinced solubility has been achieved but that does not seem a problem with existing data sets. The new patent potential could be exciting given it adds value beyond $450m.

The data sets show information that provided extra scope for the drug which will lead to further patents that will make the drug more valuable. Interesting something that impacts lung tissue?

It was a nice surprise to have a good RNS yesterday especially as the NXP002 test results were referred to in the interview last week when AR and AB were discussing the NXP004 patent. It got me wondering what if a third party had requested the information on the NXP002 results and the BOD was of the view they had to formally notify the market of the results otherwise they would create a situation of privledged information to one party.

It boils down to which pharma wants the next blockbuster IPF drug

Isn’t durability to do with how long the dose remains in the dosed tissue, therefore it is complete data only as it would determine dosage timing.

Address now on the boxes of Orient Genie are aUK compliance specialist there presumably to deal with any enquiries saves a job for ODX. Jim Bell definitely said they are U.K. made.
SENSUS Group
Medical Devices
Bishops Stortford, Herts 143 followers
EU Medical Device and In-Vitro Diagnostic regulatory and compliance specialists..

This is interesting the extension is to the end of January what are the chances another test will take over once approved
“ Manufacturer: Zhejiang Orient
Gene Biotech
Device/model name: Rapid COVID-19 (Antigen) Self-
test to detect positive cases amongst asymptomatic
people, one-off testing prior to an activity to reduce
risks, outbreak testing and asymptomatic testing.
Daily testing of contacts is not covered by this
authorisation. For supply through NHS Test and
Trace only.
Issue date: 28/05/2021
Expiry date: 31/01/2022 (extension granted)”

Dam is now, DHSC apparently from Twitter photos is happening under the radar, staff numbers growing so it’s happening